Skip to main content
Category

Press Release

Press Release

Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies

-Total gross proceeds from the transaction, before payment of transaction expenses, expected to be up to $82 million assuming no redemptions, combining a possible PIPE financing of up to $40 million and up to $42 million held in First Light trust account -Cash resources will…
Calidi Biotherapeutics
January 9, 2023
Press Release

Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs

Calidi was awarded $3.1 million to support the development of Supernova-1 (SNV1) program through IND application City of Hope, a cancer research and treatment organization, was awarded $12 million to support a Phase 1 physician-sponsored clinical trial evaluating Calidi’s licensed oncolytic virotherapy NeuroNova-2 (NNV2) platform…
Calidi Biotherapeutics
December 13, 2022
Press Release

Calidi Biotherapeutics to Present at the 7th Annual Oncolytic Virotherapy Summit

LA JOLLA, Calif. (December 6, 2022) -- Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, today announced an upcoming presentation at the 7th Annual Oncolytic Virotherapy Summit, taking place in Boston, Massachusetts and virtually, December 6-8, 2022.…
Calidi Biotherapeutics
December 6, 2022
Press Release

Calidi Biotherapeutics Presents Promising Pre-Clinical Data from SuperNova-1 (SNV1), a Novel Oncolytic-Cell Based Platform, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)

LA JOLLA, CALIF (November 7, 2022) -- Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, today announced the presentation of new pre-clinical data from the company’s SuperNova-1 (SNV1) platform at the upcoming Society for…
Calidi Biotherapeutics
November 7, 2022
Press Release

Calidi Biotherapeutics to Present Pre-Clinical SuperNova1 (SNV1) Data at the 2022 SITC Annual Meeting

LA JOLLA, CALIF (October 12, 2022)-- Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, today announced a poster presentation highlighting pre-clinical data from the company’s SuperNova1 (SNV1) program at the upcoming Society for Immunotherapy of…
Calidi Biotherapeutics
October 12, 2022
Press Release

Calidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma

LA JOLLA, CALIF--August 2, 2022--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, is pleased to announce that City of Hope has received U.S. Food and Drug Administration (FDA) authorization to proceed with a…